26 completed, 12 terminated, 3 unknown, 2 withdrawn. 28 Phase 2, 13 Phase 3, 10 Phase 1, 1 Phase 4.
Follow Soliris: new trials by email Literature Review of Soliris trials Research Report on Soliris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-01-01 | 2026-04-13 |
| Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation Eculizumab - Kidney Transplantation | Phase 1 / Phase 2 | Unknown | Tao Lin | 30 | 2024-07-01 | 2024-06-13 |
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 3 | 2022-10-06 | 2025-04-08 |
| A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment Ravulizumab, Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 202 | 2022-08-01 | 2026-04-30 |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy Eculizumab, Ravulizumab, BCX9930 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Terminated | BioCryst Pharmaceuticals | 12 | 2021-12-06 | 2025-03-07 |
| Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx Imlifidase, PLEX, IVIg - Kidney Transplantation in Highly Sensitized Patients | Phase 3 | Completed | Hansa Biopharma AB | 64 | 2021-10-14 | 2026-04-30 |
| Complement Regulation to Undo Systemic Harm in Preeclampsia Eculizumab - Preeclampsia, Severe Preeclampsia | Phase 2 | Terminated | Cedars-Sinai Medical Center | 2 | 2021-09-13 | 2023-11-29 |
| Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab Eculizumab, Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria | Phase 4 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2021-04-14 | 2024-09-05 |
| A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome Eculizumab, Placebo - Guillain-Barre Syndrome | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 57 | 2021-03-08 | 2025-09-08 |
| The Use of Eculizumab in HELLP Syndrome Eculizumab - HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality | Phase 1 | Completed | Johns Hopkins University | 3 | 2021-02-23 | 2023-11-14 |
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria BCD-148, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Biocad | 28 | 2019-04-04 | 2021-02-12 |
| A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH ABP 959, Eculizumab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Amgen | 42 | 2019-01-22 | 2023-05-23 |
| Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® BCD-148, Soliris - Healthy Subjects | Phase 1 | Completed | Biocad | 78 | 2018-09-21 | 2020-05-15 |
| Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Eculizumab - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 23 | 2018-08-03 | 2023-09-21 |
| Transcriptome and Metabolic Analyses of CHAPLE Disease Eculizumab Injection - CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis | Unknown | Marmara University | 60 | 2018-06-15 | 2019-08-14 | |
| Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Pegcetacoplan, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 80 | 2018-06-14 | 2022-03-25 |
| Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab Danicopan, Eculizumab - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 12 | 2018-05-08 | 2023-12-12 |
| Complement Inhibitor Eculizumab in Clinical Islet Transplantation Eculizumab - Diabetes Mellitus | Phase 2 | Completed | Uppsala University | 3 | 2016-05-15 | 2018-10-04 |
| Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation Eculizumab - Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation | Phase 1 / Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2015-02-01 | 2025-11-20 |
Showing 20 of 46. Sign in to see all of them.
Hemoglobinuria, Paroxysmal (12) · Neuromyelitis Optica (4) · Delayed Graft Function (3) · Demyelinating Diseases (3) · Myelitis, Transverse (3) · Optic Neuritis (3) · Recurrence (3) · HELLP Syndrome (2) · Kidney Failure, Chronic (2) · Rejection, Psychology (2) · Thrombotic Microangiopathies (2) · Acute Lung Injury (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Antiphospholipid Syndrome (1) · Atypical Hemolytic Uremic Syndrome (1)
Alexion Pharmaceuticals, Inc. (14) · Mayo Clinic (3) · Biocad (2) · Cedars-Sinai Medical Center (2) · Johns Hopkins University (2) · Regeneron Pharmaceuticals (2) · Amgen (1) · Apellis Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · BioCryst Pharmaceuticals (1) · Brigham and Women's Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · Hadassah Medical Organization (1) · Hansa Biopharma AB (1) · Heeger, Peter, M.D. (1)
United States (30) · Italy (12) · United Kingdom (12) · Spain (11) · France (8) · Australia (7) · Canada (7) · Germany (7) · Japan (6) · Russia (6) · South Korea (5) · Sweden (5) · Turkey (Türkiye) (5) · Czechia (4) · Malaysia (3)
Anil K Chandraker, MD (1) · Arthur J Vaught (1) · Austin G Kulasekararaj, MBBS, MD (1) · Benjamin Philosophe, MD, PHD (1) · Bernd Schroppel, MD (1) · Dror Mevorach, MD (1) · Gunnar Tufveson, MD, PhD (1) · Jeffrey Laurence, MD (1) · Jignesh Patel, M.D., Ph.D. (1) · Mark D Stegall (1) · Mark D. Stegall, M.D. (1)
PMID 33676197, PMID 34498507, PMID 17702897, PMID 21222185, PMID 21942930, PMID 23512355, PMID 23623397, PMID 23934275, PMID 24289920, PMID 24354307, PMID 24408973, PMID 24990476, PMID 25654478, PMID 27568864, PMID 30887675, PMID 31050279, PMID 32990324, PMID 33251691, PMID 33310418, PMID 33730455, PMID 34314483, PMID 34445916, PMID 34803867, PMID 35514201, PMID 35796199, PMID 35869984, PMID 36055332, PMID 37182818, PMID 37314061, PMID 37707673, PMID 37946262, PMID 38593241, PMID 38727860, PMID 38987228, PMID 39079163, PMID 39171864, PMID 40285403, PMID 40720060, PMID 42763038
2019 (2), 2014 (1), 2016 (1), 2023 (1), K12HD085845 (1), P01DK058335 (1), UL1TR000135 (1), ZIAAI000717-22 (1)